BGPartner advises EQT, Forbion and Jeito on extension of Series B financing of Noema Pharma Ltd to $147 mio

Noema Pharma Ltd, a Swiss clinical-stage biotech company advancing treatments for debilitating central nervous system (CNS) disorders, has successfully closed a Series B extension, raising an additional $27 million. This brings the total funding in this round to an impressive $147 million. 

This extension was made possible through additional investment from EQT Life Sciences and continued backing support from Forbion, Jeito Capital and other leading investors. 

The financing will support Noema Pharma Ltd to advance four active Phase 2 trials targeting severe pain in trigeminal neuralgia and seizures in tuberous sclerosis complex, Tourette syndrome and childhood-onset fluency disorder. 

BGPartner advised EQT, Forbion and Jeito on all Swiss legal matters and the negotiations of this Series B extension and the initial Series B round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate).

BGPartner – Mastering Law and Negotiation